7 studies found for:    "methodist hospital" | Open Studies | "Prostatic Neoplasms" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
2 Recruiting TAA-Specific CTLS for Solid Tumors (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
3 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
4 Recruiting Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer
Condition: Localized Prostate Cancer
Intervention: Drug: Ad5-SGE-REIC/Dkk3
5 Recruiting Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: abiraterone;   Drug: prednisone
6 Recruiting ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
Condition: Bone Metastases
Intervention: Device: ExAblate 2100
7 Recruiting CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza

Indicates status has not been verified in more than two years